Imunon Inc Net Income
| IMNN Stock | USD 3.42 0.04 1.16% |
As of the 12th of February 2026, Imunon retains the Risk Adjusted Performance of (0.02), market risk adjusted performance of (1.04), and Standard Deviation of 4.14. Imunon technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Imunon Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 4.0043 | Revenue | Earnings Share (12.53) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -16.8 M | -17.6 M | |
| Net Loss | -16.8 M | -17.6 M | |
| Net Loss | -32.3 M | -33.9 M | |
| Net Loss | (18.99) | (19.94) | |
| Net Income Per E B T | 0.84 | 0.89 |
Imunon | Net Income | Build AI portfolio with Imunon Stock |
Evaluating Imunon's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Imunon Inc's fundamental strength.
Latest Imunon's Net Income Growth Pattern
Below is the plot of the Net Income of Imunon Inc over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Imunon Inc financial statement analysis. It represents the amount of money remaining after all of Imunon Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Imunon's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Imunon's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (18.62 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Imunon Net Income Regression Statistics
| Arithmetic Mean | (19,397,781) | |
| Coefficient Of Variation | (38.71) | |
| Mean Deviation | 5,163,547 | |
| Median | (20,402,176) | |
| Standard Deviation | 7,509,071 | |
| Sample Variance | 56.4T | |
| Range | 34M | |
| R-Value | (0.20) | |
| Mean Square Error | 57.8T | |
| R-Squared | 0.04 | |
| Significance | 0.44 | |
| Slope | (295,419) | |
| Total Sum of Squares | 902.2T |
Imunon Net Income History
Other Fundumenentals of Imunon Inc
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Imunon Net Income component correlations
Imunon Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Imunon is extremely important. It helps to project a fair market value of Imunon Stock properly, considering its historical fundamentals such as Net Income. Since Imunon's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Imunon's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Imunon's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Imunon diversify its offerings? Factors like these will boost the valuation of Imunon. Market participants price Imunon higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Imunon data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Imunon Inc requires distinguishing between market price and book value, where the latter reflects Imunon's accounting equity. The concept of intrinsic value - what Imunon's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Imunon's price substantially above or below its fundamental value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Imunon's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Imunon 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Imunon's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Imunon.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Imunon on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Imunon Inc or generate 0.0% return on investment in Imunon over 90 days. Imunon is related to or competes with Sensei Biotherapeutics, Dogwood Therapeutics, Bolt Biotherapeutics, Evogene, Cellectar Biosciences, Cocrystal Pharma, and AEON Biopharma. Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immu... More
Imunon Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Imunon's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Imunon Inc upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 21.83 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 6.74 |
Imunon Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Imunon's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Imunon's standard deviation. In reality, there are many statistical measures that can use Imunon historical prices to predict the future Imunon's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (1.05) |
Imunon February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (1.04) | |||
| Mean Deviation | 3.08 | |||
| Coefficient Of Variation | (2,969) | |||
| Standard Deviation | 4.14 | |||
| Variance | 17.11 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (1.05) | |||
| Maximum Drawdown | 21.83 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 6.74 | |||
| Skewness | 0.9062 | |||
| Kurtosis | 2.02 |
Imunon Inc Backtested Returns
Imunon Inc holds Efficiency (Sharpe) Ratio of -0.0639, which attests that the entity had a -0.0639 % return per unit of risk over the last 3 months. Imunon Inc exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Imunon's Standard Deviation of 4.14, risk adjusted performance of (0.02), and Market Risk Adjusted Performance of (1.04) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.14, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Imunon's returns are expected to increase less than the market. However, during the bear market, the loss of holding Imunon is expected to be smaller as well. At this point, Imunon Inc has a negative expected return of -0.27%. Please make sure to check out Imunon's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Imunon Inc performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.31 |
Below average predictability
Imunon Inc has below average predictability. Overlapping area represents the amount of predictability between Imunon time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Imunon Inc price movement. The serial correlation of 0.31 indicates that nearly 31.0% of current Imunon price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.31 | |
| Spearman Rank Test | 0.33 | |
| Residual Average | 0.0 | |
| Price Variance | 0.07 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Imunon Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Imunon Inc reported net income of (18.62 Million). This is 105.46% lower than that of the Biotechnology sector and 126.58% lower than that of the Health Care industry. The net income for all United States stocks is 103.26% higher than that of the company.
Imunon Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Imunon's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Imunon could also be used in its relative valuation, which is a method of valuing Imunon by comparing valuation metrics of similar companies.Imunon is currently under evaluation in net income category among its peers.
Imunon Current Valuation Drivers
We derive many important indicators used in calculating different scores of Imunon from analyzing Imunon's financial statements. These drivers represent accounts that assess Imunon's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Imunon's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 26.1M | 3.4M | 11.1M | 7.1M | 8.1M | 7.7M | |
| Enterprise Value | 15.1M | (9.6M) | 5.9M | 2.9M | 3.3M | 3.1M |
Imunon ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Imunon's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Imunon's managers, analysts, and investors.Environmental | Governance | Social |
Imunon Institutional Holders
Institutional Holdings refers to the ownership stake in Imunon that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Imunon's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Imunon's value.| Shares | Fmr Inc | 2025-03-31 | 876 | Group One Trading, Lp | 2025-03-31 | 129 | Bank Of America Corp | 2025-03-31 | 124 | Federation Des Caisses Desjardins Du Quebec | 2025-03-31 | 66.0 | Ubs Group Ag | 2025-03-31 | 22.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 16.0 | Game Plan Financial Advisors, Llc | 2025-03-31 | 2.0 | Citadel Advisors Llc | 2025-03-31 | 0.0 | Hrt Financial Llc | 2025-03-31 | 0.0 | Geode Capital Management, Llc | 2025-03-31 | 143.4 K | Blackrock Inc | 2025-03-31 | 58.2 K |
Imunon Fundamentals
| Return On Equity | -2.33 | ||||
| Return On Asset | -0.78 | ||||
| Current Valuation | 7.62 M | ||||
| Shares Outstanding | 3.4 M | ||||
| Shares Owned By Insiders | 1.05 % | ||||
| Shares Owned By Institutions | 5.32 % | ||||
| Number Of Shares Shorted | 255.52 K | ||||
| Price To Book | 2.88 X | ||||
| Price To Sales | 17.94 X | ||||
| Gross Profit | 2.72 M | ||||
| EBITDA | (17.9 M) | ||||
| Net Income | (18.62 M) | ||||
| Cash And Equivalents | 42.11 M | ||||
| Cash Per Share | 5.93 X | ||||
| Total Debt | 1.14 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 6.52 X | ||||
| Book Value Per Share | 1.41 X | ||||
| Cash Flow From Operations | (18.85 M) | ||||
| Short Ratio | 4.57 X | ||||
| Earnings Per Share | (12.53) X | ||||
| Target Price | 21.5 | ||||
| Number Of Employees | 25 | ||||
| Beta | 2.06 | ||||
| Market Capitalization | 11.77 M | ||||
| Total Asset | 9.72 M | ||||
| Retained Earnings | (406.8 M) | ||||
| Working Capital | 3.22 M | ||||
| Net Asset | 9.72 M |
About Imunon Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Imunon Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Imunon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Imunon Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Imunon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.Moving together with Imunon Stock
Moving against Imunon Stock
| 0.57 | DSGN | Design Therapeutics | PairCorr |
| 0.57 | ENGN | enGene Holdings Common | PairCorr |
| 0.51 | IMMP | Immutep Ltd ADR | PairCorr |
The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.
The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Will Biotechnology sector continue expanding? Could Imunon diversify its offerings? Factors like these will boost the valuation of Imunon. Market participants price Imunon higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Imunon data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Imunon Inc requires distinguishing between market price and book value, where the latter reflects Imunon's accounting equity. The concept of intrinsic value - what Imunon's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Imunon's price substantially above or below its fundamental value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Imunon's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.